bioAffinity Publishes Clinical Framework for CyPath® Lung
bioAffinity Technologies, Inc. announced the publication of a comprehensive clinical review and white paper authored by its Chief Medical Officer, Gordon H. Downie, MD, PhD. The paper presents a practical clinical framework for integrating CyPath® Lung into pulmonary nodule evaluation and cancer surveillance. It outlines specialty-specific approaches for pulmonology, primary care, and oncology practices, emphasizing the test's noninvasive nature and its ability to provide objective, real-time information from the lung microenvironment.
Key Highlights
- bioAffinity Technologies published a comprehensive clinical review and white paper.
- Authored by Chief Medical Officer Gordon H. Downie, MD, PhD.
- Presents a practical clinical framework for incorporating CyPath® Lung.
- Focuses on pulmonary nodule evaluation and cancer surveillance.
- Outlines specialty-specific approaches for pulmonology, primary care, and oncology practices.
- Highlights CyPath® Lung's noninvasive sputum analysis for lung microenvironment data.
- 7,783,061 outstanding shares of common stock as of July 24, 2026.
- Aggregate market value of common stock was approximately $5.1 million as of July 24, 2026.
Price Impact
More from BIAF
bioAffinity Technologies Calls Special Meeting for Warrant, Share Authorization Votes
bioAffinity Technologies Reports Q2 Net Loss of $3.37M; Going Concern Doubt
bioAffinity Q2 Revenue $1.5M, Net Loss $3.4M; CyPath Lung Volume +216%